Table 1 Baseline characteristics compared between HFpEF and controls
Characteristics | HFpEF (n = 79) | Controls (n = 158) | p-value |
|---|---|---|---|
Age (years) | 71.6 ± 11.5 | 70.6 ± 10.0 | 0.491 |
Male gender | 29 (36.7%) | 58 (36.7%) | 1.000 |
Body mass index (kg/m2) | 26.8 ± 5.6 | 26.6 ± 4.6 | 0.767 |
NYHA-II | 68 (86.1%) | – | – |
NYHA-III | 11 (13.9%) | – | – |
Hyperlipidemia | 51 (64.6%) | 116 (73.4%) | 0.159 |
Diabetes | 44 (55.7%) | 85 (53.8%) | 0.782 |
Hypertension | 61 (77.2%) | 114 (72.2%) | 0.403 |
History of myocardial infarction | 5 (6.3%) | 0 (0.0%) | 0.164 |
History of revascularization | 7 (8.9%) | 0 (0%) | 0.333 |
History of atrial fibrillation | 19 (24.1%) | 2 (1.3%) |  < 0.001 |
Mitral regurgitation | 28 (35.4%) | 21 (13.3%) |  < 0.001 |
Medication use†|  |  |  |
 Aspirin | 28 (43.1%) | 63 (47.4%) | 0.569 |
 Statin | 43 (66.2%) | 95 (71.4%) | 0.448 |
 β-blockers | 38 (58.5%) | 77 (57.9%) | 0.939 |
 ACEi | 9 (13.8%) | 16 (12.0%) | 0.718 |
 ARB | 18 (27.7%) | 42 (31.6%) | 0.576 |
 Diuretics | 27 (41.5%) | 31 (23.3%) | 0.008 |